Protease Inhibitors for the Treatment of SARS-CoV-2

1
SARS-CoV-2 Introduction
2
SARS-CoV-2 Outbreak Process
January, 2020 - Named 2019-nCoV February 11,
2020 - Named SARS-CoV-2
End of 2019 - Wuhan, China January 30, 2020 -
PHEIC Now Spread in over 200 countries (WHO)
3
Coronaviruses Family
The SARS-CoV-2 virus that causes COVID-19 belongs
to the Coronaviridae family.
Birds and Mammals
Mammals
SARS-CoV-2
4
SARS-CoV-2 Structure
Spike Glycoprotein (S) Get the virus into the cell
M-Protein Virus germination and envelope formation
Hemagglutinin-esterase (HE) May facilitate the
virus to initially adsorb the cell membrane
RNA and N Protein N protein is related to the
formation of nucleocapsid in RNA genome
E-Protein The smallest and most mysterious
Envelope
5
SARS-CoV-2 Life Cycle
1
4 Release
Fusion
ACE2
2 Replicate
3
Assembly
6
SARS-CoV-2 Treatment Strategies
1
2
3
Use existing molecular libraries and databases
to screen for molecules that may have a
therapeutic effect on SARS-CoV-2.
Screen the existing broad-spectrum antiviral
drugs.
Develop specific drugs based on the genomic
information and pathological characteristics of
SARS-CoV-2.
7
Object of Specific Drugs
3-1. Target to the Host

• Enhance immune response - such as the release of
  interferon.

• Block the signal pathways required for virus
  replication.

• Target viral and cell surface receptor proteins
  (ACE2).

8
Object of Specific Drugs
3-2. Target to SARS-CoV-2

• Block the viruss binding to human cell
  receptors or inhibiting the virusself-assembly
  process - target to the structural proteins of
  the virus.

• Prevent viral RNA synthesis - target to the
  genetic material of the virus.

• Inhibit virus replication - target to key
  enzymes of the virus.

9
SARS-CoV-2 Treatment Strategies
?
?
Monoclonal antibody/convalescent plasma for ACE2
Prevent the virus into the host cell.
1
Camostat mesylate Prevent SARS-CoV-2 into the
cell by acting on TMPRSS2.
2
?
Lopinavir-Ritonavir Inhibition of protease
activity of SARS-CoV-2.
3
4
Ribavirin- May inhibit mRNA capping.
?
RNA Synthesis Inhibitors Inhibits SARS-CoV-2 RNA
synthesis and replication.
5
RNA Synthesis Inhibitors
?
Neuraminidase Inhibitors (NAIs)-Interfere with
the release of progeny influenza virus from
infected host cells.
6
6
science.sciencemag.org/content/367/6485/1412
NAIs
?
10
Creative Biolabs SARS-CoV-2 Services
In Vitro Diagnostic (IVD) Development

• Antibody Immunoassay Development Services
• Molecular Diagnostic Assay Development Services
• SARS-CoV-2 Related Detection Kits

• Drug Discovery Services
• Anti-SARS-CoV-2 Drug Discovery
• SARS-CoV-2 Vaccine Discovery
• SARS-CoV-2 Preclinical Research

11
Creative Biolabs SARS-CoV-2 Products
SARS-CoV-2
MERS-CoV
SARS-CoV
Antibody Recombinant Proteins Plasmids PCR
Primers Probes Detection Kits
Antibody Recombinant Proteins Plasmids Protein
Expression Products
Antibody Recombinant Proteins Plasmids Protein
Expression Products
Other Coronavirus
RNA Extraction Kit
Key Receptor ACE2
Antibody Recombinant Proteins Plasmids Protein
Expression Products
Antibody Recombinant Proteins Plasmids Protein
Expression Products
RNA Extraction Kits
12
Web www.creative-biolabs.com
Contact Us
Email info_at_creative-biolabs.com
Address 45-1 Ramsey Road, Shirley, NY 11967, USA